Inclusion Criteria:

1. Must understand and voluntarily sign an informed consent form

2. Age >/= 18 years at the time of signing the informed consent form

3. Must be able to adhere to the study visit schedule and other protocol requirements

4. HLA-A2 positive at one allele

5. Diagnosis of myelodysplastic syndrome (MDS) and must meet all the following criteria

6. French-American-British (FAB) Class Refractory anemia (RA), Refractory Anemia with
Excess Blasts (RAEB), refractory anemia with ringed sideroblasts (RARS)

7. World Health Organization(WHO) Classification refractory anemia (RA), refractory
anemia with ringed sideroblasts(RARS), refractory cytopenia with multilineage
dysplasia (RCMD), refractory cytopenia with ringed sideroblasts (RCMD-RS) ,
refractory anemia with excess blasts type 1 (RAEB-1)

8. Less than 20% blasts on marrow aspirate

9. International Prognostic Scoring System (IPSS) risk groups Intermediate 1 or
transfusion dependent low risk.

10. Both de novo and therapy related MDS are eligible

11. Eastern Cooperative Oncology Group (ECOG) performance status = 0 or 1

12. Women of childbearing potential must have a negative serum pregnancy test within 30
days of starting study drug. A woman of child-bearing potential is a sexually mature
woman who has not undergone a hysterectomy or who has not been naturally
postmenopausal for at least 24 consecutive months (i.e., who has had menses at any
time in the preceding 24 consecutive months)

13. Male or female of child-bearing potential must agree to use adequate contraceptive
methods

14. Serum bilirubin < 2 mg/ml

15. Serum creatinine
16. Serum ALT < 2 x upper normal limit

17. anti-neutrophil cytoplasmic antibody (cANCA) negative

18. Not received specific therapy for MDS for 4 weeks. However, supportive therapy is
permitted.

Exclusion Criteria:

1. Marrow blasts on aspirate >/= 20%

2. Blood blasts > 1%

3. Inaspirable bone marrow

4. Myelosclerosis occupying >30% of marrow space

5. Iron absence on marrow examination or transferrin saturation <20% and serum ferritin
<50ng/ml

6. B-12 deficiency

7. Folate deficiency

8. History of immune related hematological disorder [i.e.,immune thrombopenia
purpura(ITP),autoimmune hemolytic anemia ( AIHA)]

9. Other causes of cytopenia not related to MDS (i.e., GI blood loss)

10. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form or that will place
the subject at unacceptable risk if he/she were to participate in the study or
confounds the ability to interpret the data

11. Prior allogeneic or syngeneic transplant

12. Prior solid organ transplant

13. Life expectancy severely limited by diseases other than MDS

14. Pregnant or lactating females

15. Prior vaccine therapy for MDS

16. Chronic use (>2 weeks) of greater than physiologic doses of a corticosteroid agent
(dose equivalent to >10 mg/day of prednisone) within 30 days of the first day of
study drug treatment. (Topical and inhaled corticosteroids are permitted)

17. Prior history of malignancy other than MDS (except basal cell or squamous cell
carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been
free of disease for >/= 5 years

18. Known allergy to incomplete Freund's adjuvant

19. Experimental therapy, cyclosporine, antithymocyte globulin, or FK506 within 3 months
of study entry

20. Treatment with androgenic hormones, danazol, colony stimulating factors,
erythropoietin, thalidomide, arsenic trioxide or other agents used to treat MDS
within four weeks of the first day of study treatment

21. refractory anemia with excess blasts in transformation (RAEB-t) (French-American
British (FAB) criteria ) or refractory anemia with excess blasts type2 (RAEB-2)
(World Health Organization (WHO) criteria)

22. Chloroma

23. Hypercalcemia

24. Progressive viral or bacterial infection. Patients are not eligible unless all
infections are resolved and the patient has remained afebrile for seven days without
antibiotics

25. Cardiac disease of symptomatic nature or cardiac ejection fraction < 40%

26. Symptomatic pulmonary disease or FEV1, FVC and Carbon Monoxide Diffusing Capacity
(DLCO)
27. History of Wegener's Granulomatosis or vasculitis

28. History of HIV positivity or AIDS

29. Prior history of AML